Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.42 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.42 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.99 - 1.995 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.42 | USD |
Spero Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 76.49M | 53.87M | - | 103.78M | 22.81M | 0.42 | 3.35 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Spero Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.50 | 1.55 | 1.37 | 1.42 | 229,588 | -0.08 | -5.33% |
| 1 Month | 1.74 | 1.81 | 1.37 | 1.61 | 229,564 | -0.32 | -18.39% |
| 3 Months | 1.53 | 1.89 | 1.33 | 1.66 | 335,613 | -0.11 | -7.19% |
| 6 Months | 1.03 | 1.89 | 0.99 | 1.53 | 248,313 | 0.39 | 37.86% |
| 1 Year | 1.69 | 1.995 | 0.99 | 1.52 | 274,306 | -0.27 | -15.98% |
| 3 Years | 13.58 | 19.87 | 0.6801 | 2.36 | 960,991 | -12.16 | -89.54% |
| 5 Years | 12.33 | 23.639 | 0.6801 | 3.56 | 641,635 | -10.91 | -88.48% |
Spero Therapeutics Description
| Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
